<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02549911</url>
  </required_header>
  <id_info>
    <org_study_id>HISA</org_study_id>
    <nct_id>NCT02549911</nct_id>
  </id_info>
  <brief_title>HIPEC, Intravenous Chemotherapy and Surgery for the Treatment of Advanced GC With Peritoneal Metastasis</brief_title>
  <official_title>Hyperthermic Intraperitoneal Chemotherapy, Intravenous Chemotherapy Combined With Surgery for the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Explore the hyperthermic intraperitoneal chemotherapy (HIPEC) and intravenous chemotherapy
      for Creating the Operation Chance in advanced gastric cancer with peritoneal metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the effectiveness and safety of Hyperthermic intraperitoneal chemotherapy,
      intravenous chemotherapy combined with surgery for the treatment of advanced gastric cancer
      with peritoneal metastasis,so as to further find out the optimal protocol for the Conversion
      therapy in the patients with advanced gastric cancer.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection</measure>
    <time_frame>3 months</time_frame>
    <description>the rate of R0 resection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Number and degree of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>3 years</time_frame>
    <description>the overall survival time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>HIPEC,Chemotherapy AND surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>surgical exploration,if PCI&lt;20,then we perform this study
HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
chemotherapy(3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )
after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HIPEC,Chemotherapy AND surgery</intervention_name>
    <description>HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )
after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles</description>
    <arm_group_label>HIPEC,Chemotherapy AND surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        gastric cancer confirmed by endoscopic biopsy , and enhanced CT suspected to have
        peritoneal metastasis, including ascites, ovarian metastasis, omentum or peritoneal
        metastasis.

          -  Definitely diagnosed as above stage of stomach cancer before the operation via CT or
             MRI, ultrasonic endoscopy and blood tumor antigen test, or through the laparoscopy if
             necessary

          -  Untreated (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy)

          -  ECOG (Eastern Cooperative Oncology Group) : 0~2

          -  Age: 18~75 years old

          -  Normal hemodynamic indices before the recruitment (including blood cell count and
             liver/kidney function). For example: WBC&gt;4.0×109/L, NEU &gt;1.5×109/L, PLT&gt;100×109/L,
             BIL&lt;1.5 times of upper limit of normal reference value, ALT and AST&lt;2.5 times of upper
             limit of normal reference value, and CRE&lt;1.2mg/dl

          -  Good cardiac function before the recruitment, no seizure of myocardial infarction in
             past half year, and controllable hypertension and other coronary heart diseases

          -  Not concomitant with other uncontrollable benign diseases before the recruitment (e.g.
             the infection in the lung, kidney and liver)

          -  Not participating in other study projects before and during the treatment

          -  Signed the Informed Consent Form

        Exclusion Criteria:

          -  Not conforming to above inclusion criteria

          -  Distal metastasis to lung, liver, or para aortic lymph node metastasis

          -  Ever operation on the stomach

          -  Operation intolerance due to other systemic basic diseases

          -  Ever administered other drugs (including TCM drugs) before the recruitment, or no
             guarantee of progress according to the study requirement after the recruitment

          -  Allergy to the drugs in this protocol

          -  Pregnant or lactating women

          -  Women at childbearing age and of pregnancy desire during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yian Du, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yian Du, MD</last_name>
    <phone>86-571-88128031</phone>
    <email>ypfzmu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pengfei Yu, MD</last_name>
    <phone>86-571-88128031</phone>
    <email>ypfzmu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yian Du, MD</last_name>
      <phone>86-571-88128031</phone>
      <email>ypfzmu@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Pengfei Yu, MD</last_name>
      <phone>86-571-88128031</phone>
      <email>ypfzmu@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yian Du, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pengfei Yu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wu X, Li Z, Li Z, Jia Y, Shan F, Ji X, Bu Z, Zhang L, Wu A, Ji J. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. J Surg Oncol. 2015 Jun;111(7):840-7. doi: 10.1002/jso.23889. Epub 2015 Apr 10.</citation>
    <PMID>25864884</PMID>
  </reference>
  <reference>
    <citation>Xia W, Hu Y, Mou T, Chen T, Yu J, Li G. [Safety and efficacy of intraperitoneal hyperthermic perfusion chemotherapy following laparoscopic palliative resection for gastric cancer patients with peritoneal metastasis]. Zhonghua Wei Chang Wai Ke Za Zhi. 2014 Nov;17(11):1087-91. Chinese.</citation>
    <PMID>25421766</PMID>
  </reference>
  <reference>
    <citation>Di Vita M, Cappellani A, Piccolo G, Zanghì A, Cavallaro A, Bertola G, Bolognese A, Facchini G, D'Aniello C, Di Francia R, Cardì F, Berretta M. The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows. Anticancer Drugs. 2015 Feb;26(2):123-38. doi: 10.1097/CAD.0000000000000179.</citation>
    <PMID>25406023</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>September 14, 2015</last_update_submitted>
  <last_update_submitted_qc>September 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>surgery</keyword>
  <keyword>Surgically-Created Resection Cavity</keyword>
  <keyword>Adverse Reaction to Drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

